WO2016136716A1 - 遺伝子特異的非バイアス増幅法 - Google Patents
遺伝子特異的非バイアス増幅法 Download PDFInfo
- Publication number
- WO2016136716A1 WO2016136716A1 PCT/JP2016/055192 JP2016055192W WO2016136716A1 WO 2016136716 A1 WO2016136716 A1 WO 2016136716A1 JP 2016055192 W JP2016055192 W JP 2016055192W WO 2016136716 A1 WO2016136716 A1 WO 2016136716A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adapter
- primer
- gene
- sequence
- strand
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
- C12Q1/6855—Ligating adaptors
Definitions
- the present invention relates to a method for specifically bias-amplifying a target gene and an adapter used therefor.
- the PCR method has been used as a method for amplifying a specific gene.
- an adapter is provided, and gene amplification has been performed using a part of the adapter and a gene-specific part as primers.
- the adapter since the adapter is added to both ends of the DNA, it has been a problem that PCR is amplified only by the adapter portion. Conventionally, it has been made possible by digestion with restriction enzymes, but this has been a technical problem.
- the conventional technique is a method of amplifying a specific gene without applying a bias by inserting a restriction enzyme site into the adapter part or the cDNA terminal part (3 ′ side) and performing a restriction enzyme treatment.
- the restriction enzyme treatment was not 100%, and there was a problem that PCR amplification occurred only at the adapter portion due to untreated DNA and residual adapter.
- An object of the present invention is to provide a method for amplifying a target gene without applying a bias, and an adapter used therefor.
- the present inventors do not perform restriction enzyme treatment, give the adapter part uracil that does not exist in normal DNA, digest it with uracil DNA glycosylase, and part of the adapter part (sense or antisense DNA) It was found that the PCR amplification with only the adapter portion can be prevented by removing the (strand), and the present invention has been completed.
- the gene-specific non-bias amplification method of the present invention has made it possible to amplify specific genes without applying a bias.
- Double-stranded adapter DNA used for non-biased gene amplification having the following characteristics: (a) the sense strand and the antisense strand are annealed, and the base length of the sense strand and the antisense strand is the same or the sense strand is long; (b) the base length of the sense strand is 15-40 bp; (c) The antisense strand contains a plurality of uracils, and the adapter is treated with uracil DNA glycosylase (UNG) to remove uracil, followed by heat treatment to degrade the antisense strand; (d) at least one end of the adapter DNA has a blunt-ended form; (e) binds to the target gene to be amplified at one end; and (f) part or all of the sense strand is the forward primer sequence used for gene amplification.
- UNG uracil DNA glycosylase
- [2] The double-stranded adapter DNA of [1], wherein the number of uracils contained in the antisense strand is 10 to 25% of the number of bases of the antisense strand, and uracil is present every 5 to 10 bases.
- [3] The double-stranded adapter DNA of [1] or [2], wherein a phosphate group is bonded to the 5 ′ end of the antisense strand and an amino group is bonded to the 3 ′ end.
- a non-biased gene amplification kit comprising the adapter DNA of any one of [1] to [3] and a primer consisting of part or all of the sense strand of the adapter DNA.
- [5] Unbiased gene amplification by inhibiting gene amplification using only forward primer in adapter ligation PCR amplification method using forward primer consisting of double-stranded adapter DNA and partial sequence of sense strand of double-stranded adapter DNA
- An inhibitory primer used to perform (a) The sequence of the inhibition primer is (i) The whole or part of the anchor sequence part of the anchor oligo dT primer in which the anchor sequence is linked to the 5 ′ end of the oligo dT primer used when synthesizing single-stranded cDNA from the mRNA of the target gene to be amplified Consists of an array, or (ii) a partial sequence of the sense strand of the double-stranded adapter used in the adapter ligation PCR amplification method, comprising a sequence existing 3 ′ from the sequence of the forward primer, (b) An inhibitory primer whose 3 ′ side is modified with a phosphate group, amino group or dideoxyl NTP.
- [6] An unbiased gene amplification kit comprising the adapter DNA of any one of [1] to [3], a primer comprising a part or all of the sense strand of the adapter DNA, and the inhibition primer of [5].
- UNG uracil DNA glycosy
- extension reaction using only the forward primer does not occur, the extension reaction using the reverse primer occurs, and after the complementary strand of the sense strand of the adapter is formed, the forward primer anneals to the complementary strand and the extension reaction occurs.
- a method of amplifying the target gene of [7] by PCR without biasing in one direction in which the extension by 1 and extension by a forward primer occur in one direction in this order.
- a primer that synthesizes cDNA from total RNA extracted from T cells or B cells and, as a reverse primer, specifically anneals to the T cell receptor (TCR) or the sequence of the C region of the B cell receptor (BCR) A method for analyzing a repertoire of TCR or BCR, comprising comprehensively amplifying a repertoire of a TCR gene or BCR gene using the method according to [7] or [8] and performing sequencing using a sequencer.
- the gene amplification method by adapter ligation PCR using the adapter containing uracil of the present invention made it possible to amplify specific genes without applying a bias.
- the gene amplification method of the present invention can comprehensively amplify various repertoires of T cell receptor (TCR) and B cell receptor (BCR), perform sequencing using next-generation sequencers, Enables BCR repertoire analysis.
- TCR T cell receptor
- BCR B cell receptor
- This method is superior to the conventional adapter ligation PCR (AL-PCR) in all aspects, and is superior to all currently available methods, and can be said to be an unbiased gene amplification method.
- FIG. 5 is a diagram showing that five types of mouse TCRs having different sizes are equally biased and amplified by the method of the present invention. It is a figure which shows the abundance ratio of the mouse
- the present invention is a method for amplifying a target gene to be amplified without applying a bias, and is an adapter ligation PCR amplification method using an unbiased gene amplification adapter having a specific sequence.
- PCR amplification does not occur only in the adapter part, PCR Amplification proceeds in only one direction. PCR progressing in one direction is also called PCR having polarity.
- the present invention also includes a method of amplifying a specific gene without bias using an inhibitory primer.
- the adapter of the present invention is a double-stranded DNA consisting of a sense strand and an antisense strand, which are annealed.
- the adapter is also referred to as adapter DNA.
- One strand of the adapter contains uracil (dUTP: deoxyuridine triphosphate) at a certain frequency.
- uracil dUTP: deoxyuridine triphosphate
- the sense strand and the antisense strand can be replaced.
- the base corresponding to uracil of the antisense strand in the sense strand portion complementary to the antisense strand is adenine.
- the base length of the sense strand and the antisense strand may be the same, and the antisense strand containing uracil may be short.
- the adapter has a blunt end configuration at least at one end. When the antisense strand is shorter than the sense strand, one end of the adapter has a blunt end form and the other end has a protruding end form, which is ligated to the target gene to be amplified on the blunt end side. Use. When the base length of the sense strand is the same as that of the antisense strand, both ends of the adapter have a blunt end form.
- a primer comprising a sequence contained in the sense strand of the adapter is used as a forward primer. Therefore, in order to prevent the forward primer from annealing other than the adapter, the adapter sequence is not present in the genome of the organism to be amplified, or is an artificial sequence that is extremely infrequent.
- the adapter base sequence is a sequence that does not exist in the target family gene to be amplified. For example, when gene amplification is performed for the purpose of analyzing a repertoire of T cell receptors and B cell receptors, the sequence is not present in the T cell receptor or B cell receptor. As a result, unless the adapter is ligated to the end of the target gene, amplification does not occur with a primer comprising a sequence contained in the sense strand of the adapter.
- the base length of the adapter is 15 to 40 bases, preferably 20 to 35 bases, more preferably 20 to 30 bases.
- the base length of the short antisense strand is 10 to 20 bases, preferably 10 to 15 bases.
- the uracil contained in the antisense strand is present such that the uracil is removed by uracil DNA glycosylase (UNG) to form an abasic site, and then the entire antisense strand is decomposed by the decomposition of the abasic site by heat treatment.
- the number of bases is 10 to 50% of the total number of bases, preferably 10 to 25% of bases, more preferably 10 to 20% or 12 to 20%
- the base may be uracil.
- Uracil is not necessarily required to appear regularly in the antisense strand, but for example, it is designed to appear every 3 to 15 bases, preferably every 3 to 10 bases, and more preferably about every 5 bases.
- uracil is not present unevenly but is present uniformly throughout the entire antisense.
- the adapter sequence is designed so that the GC content is around 50%, that is, 40-60%, preferably 45-55%. Furthermore, it is preferable that there is no continuous base sequence. However, when a restriction enzyme site is included in the adapter part, A may appear continuously in the sense strand. In this case, 2 to 3 uracils may partially exist in succession in the antisense strand, but this case is acceptable.
- a phosphate group is bound to the 5 ′ end of the antisense strand on the blunt end side for ligation to the target gene. That is, the 5 ′ end of the antisense strand whose end (binding side end) that binds to the target gene is the 5 ′ end is phosphorylated in advance. By phosphorylating only one end in this way, the adapter cannot be ligated to the target gene at the end opposite to the end phosphorylated even when both ends of the adapter have a blunt end form. . When one end has a blunt end and the other end has a protruding end, the target gene is ligated only on the blunt end side.
- a modification that inhibits the PCR extension reaction is linked to the 3 ′ end of the antisense strand.
- the antisense strand contains uracil, and the antisense strand is decomposed by treatment with uracil DNA glycosylase (UNG) and heating, so that the primer does not bind to the adapter portion and an extension reaction does not occur.
- UNG uracil DNA glycosylase
- uracil DNA glycosylase UNG
- uracil DNA glycosylase breaks the uracil glucoside bond, removes uracil, and generates an alkali-sensitive abasic site in the antisense strand DNA of the adapter.
- the abasic site from which uracil has been removed is decomposed by heat treatment at 80 to 90 ° C. for several minutes, and the antisense strand of the adapter is completely decomposed.
- the adapter forward primer to be annealed to the adapter portion is designed with the whole or part of the sense strand of the adapter.
- it is a sequence consisting of 10 to 30 bases, preferably 15 to 25 bases from the 5 ′ end of the sense strand.
- the adapter of the present invention can be prepared by synthesizing and annealing a sense strand and an antisense strand by a known method.
- An antisense strand containing uracil may be synthesized using dUTP.
- Examples of the adapter of the present invention include adapters having the following sequences.
- An amino group may be bonded to the 3 ′ end of the antisense strand.
- This adapter has a blunt end at the end to which a phosphate group is bonded, and a protruding end at the other end.
- a primer consisting of the base sequence represented by SEQ ID NO: 4 is used as a forward primer.
- An amino group may be bonded to the 3 ′ end of the antisense strand.
- This adapter has a blunt end configuration at both ends.
- a primer having a base sequence represented by SEQ ID NO: 17 is used as a forward primer.
- This adapter has a blunt end configuration at both ends.
- a primer having a base sequence represented by SEQ ID NO: 17 is used as a forward primer.
- the present invention also includes a non-biased gene amplification kit comprising the above-mentioned adapter and a primer composed of part or all of the sense strand of the adapter.
- the kit may contain a reverse primer specific for the target gene, DNA polymerase, deoxyribonucleotide, and the like.
- the inhibitor primer detailed in 4 below may be included.
- the gene amplification method of the present invention uses, as a forward primer, an adapter forward primer consisting of all or part of the above-mentioned adapter sense strand and having a sequence inherent in the adapter sense strand.
- an adapter forward primer consisting of all or part of the above-mentioned adapter sense strand and having a sequence inherent in the adapter sense strand.
- a reverse primer a primer that anneals near the 3 ′ end of the target gene to be amplified is used.
- the target gene targeted by the gene amplification method of the present invention is not limited, and any genomic DNA is targeted.
- the synthesis of cDNA can be performed by a known method using a primer for synthesis specific to the gene of interest and reverse transcriptase.
- an oligo dT primer or an anchor oligo dT primer linked with an anchor sequence may be used.
- the anchor sequence of the anchor oligo dT primer is a sequence that is linked to the 5 ′ side of the oligo dT sequence and is not complementary to the target gene sequence, and includes, for example, a restriction enzyme site. 4. It may contain the sequence of the inhibition primer described in detail.
- the base length of the anchor sequence is not limited, but is 10 to 40 bases.
- a complementary DNA strand is synthesized with the synthesized single-stranded cDNA to synthesize a double-stranded cDNA.
- the species of cell origin is not limited, but preferably a eukaryotic cell, more preferably a mammalian cell, particularly preferably a human or mouse cell.
- a series of cDNAs can be synthesized using a commercially available cDNA synthesis kit. When the adapter is bound (ligated), it is necessary to blunt the ends of the original DNA, for example, synthesized cDNA or genomic DNA.
- the adapter of the present invention is ligated to both ends of the synthesized double-stranded cDNA using DNA ligase.
- DNA ligase room temperature DNA ligase such as T4 DNA ligase, E. coli DNA ligase and the like can be used.
- a heat-resistant DNA ligase may also be used.
- the adapter-ligated gene is treated with uracil DNA glucosylase (UNG).
- the treatment may be performed at 20-30 ° C. for 5-30 minutes.
- Treatment with uracil DNA glucosylase (UNG) breaks uracil glucoside bonds, removes uracil, and generates an alkali-sensitive abasic site in the antisense strand DNA of the adapter.
- heat treatment is performed at 80 to 100 ° C., for example, 95 ° C. for several minutes, for example, 2 minutes, whereby the abasic site from which uracil has been removed is degraded, and the antisense strand of the adapter is completely degraded.
- the antisense strand of the adapter that is present in excess can be degraded. If the adapter is present in excess, the antisense strand of the free adapter can act as a primer and unintentional amplification can occur, and unintentional amplification can be achieved by degrading the antisense strand of the free adapter. It can be avoided. As a result, only the sense strand of the adapter remains.
- uracil DNA glucosylase a temperature-sensitive one is preferably used. By using a temperature sensitive enzyme, the enzyme itself can be inactivated by heat treatment.
- a PCR extension reaction is carried out by adding a forward primer for adapter, which is a forward primer consisting of all or part of the sense strand of the adapter, and a reverse primer specific to the target gene and specific to the target gene.
- the adapter forward primer is designed with a sequence of all or part of the sense strand of the adapter. Preferably, it is a sequence consisting of 10 to 30 bases, preferably 15 to 25 bases from the 5 ′ end of the sense strand.
- the adapter primer anneals to the antisense strand that is complementary to the sense strand of the adapter, but even if there is one to several, preferably one or two mismatches to the antisense strand sequence.
- the reverse primer consists of a base sequence complementary to the sequence near the 3 ′ end of the target gene, and is a sequence consisting of 10 to 30 bases, preferably 15 to 25 bases. Further, there may be 1 to several, preferably 1 or 2 mismatches with respect to the base sequence of the target gene, and it may have a sequence capable of hybridizing to the target gene under stringent conditions. That's fine.
- the PCR extension reaction may be carried out by a known method using DNA polymerase under conditions usually used. For example, heating may be performed at 98 ° C. for 10 seconds, cooling at 60 ° C. for 30 seconds, and heating at 68 ° C. for 60 seconds may be repeated for about 30 cycles.
- the forward primer does not anneal with the antisense strand, so that the amplification reaction by the forward primer does not occur at first.
- the reverse primer anneals near the 3 ′ end of the sense strand of the target gene, and the amplification reaction proceeds.
- DNA synthesis proceeds by the reverse primer, it extends to the complementary strand of the sense strand of the adapter portion, and when the complementary strand is formed, the forward primer anneals to the complementary strand portion of the antisense strand of the adapter, and amplification by the forward primer Progresses.
- the forward primer does not anneal to the adapter, and thus amplification using only the forward primer does not proceed.
- amplification does not occur only with the forward primer, but the forward primer anneals to DNA extended by the reverse primer, and only amplification by the forward primer and the reverse primer occurs.
- amplification in one direction means this.
- the gene amplification method of the present invention it is possible to amplify a gene without applying a bias while maintaining the abundance ratio of each mRNA in the cell.
- the principle of the gene amplification method of the present invention and the target gene (in the middle black) The positional relationship among the indicated double strand), adapter and primer is shown in FIG.
- Fig. 1A the double strands of the 5 'long strand (sense strand) and the 3' short strand (antisense strand) existing at both ends of the gene indicate adapters. It shows that the short chain is decomposed by UNG treatment and heat treatment.
- the figure in B shows that after the antisense strand is degraded, amplification occurs in the direction of the arrow 1 with the target gene-specific reverse primer, and the forward primer that binds to the adapter after extending to the complementary strand to the sense strand of the adapter. Amplification occurs in the direction of the arrow.
- T cell receptors and B cell receptors are generated by somatic cell recombination using gene regions (segments), and include V (variable) regions, D (diversity) regions, J (joining) regions, and C ( constant) region exists.
- Recombination (reconstitution) known as V (D) J recombination expands the repertoire of T and B cell receptors and acquires approximately 10 20 diversity. According to the gene amplification method of the present invention, the repertoire of these various T cell receptors and B cell receptors can be analyzed.
- total mRNA is extracted and purified from T cells of mammals such as humans and mice, and the TCR gene is amplified by the gene amplification method of the present invention.
- total mRNA may be extracted and purified from spleen cells or spleen tissue.
- the gene amplification may be carried out by the method described in 2 above.
- a reverse primer that specifically anneals to the base sequence of the C region may be used. Since the C region is a constant region, there are few sequence variations, and all T cell receptor genes can be amplified by using one kind or several kinds of reverse primers.
- an adapter is added to the 5 ′ end of the T cell receptor gene, and PCR is carried out using a forward primer for the adapter and a C region specific primer. Can be amplified uniformly.
- ⁇ ⁇ Repertoire can be analyzed by sequencing the amplified gene.
- a next-generation sequencer (second generation sequencer) that can simultaneously determine the base sequences of tens of millions of DNA fragments may be used.
- FLX GD
- FuSeq Illumina
- This method makes it possible, for example, to analyze a T cell receptor repertoire of T cell receptors of a patient suffering from a certain disease and identify a disease-specific T cell receptor.
- the base sequence match rate is high, and there are 80% or more genes with 90% base sequence match. That is, specific gene amplification is accurately performed by the method of the present invention.
- the ratio of the repertoire of antigen receptors such as T cell receptor (TCR) and B cell receptor (BCR) in vivo can be reflected.
- Inhibitory Primer The present invention also includes an inhibitory primer used for non-biased gene amplification in the adapter ligation PCR amplification method.
- a specific gene can be amplified without applying a bias using the inhibitory primer of the present invention.
- an inhibitory primer using a partial base sequence of the adapter as a primer may be designed so that the antisense strand cannot be amplified using the adapter portion as a primer.
- the sequence of the inhibitor primer, which is a partial base sequence of the adapter is designed to be located 3 ′ side, that is, on the target gene side from the sequence of the forward primer that anneals to the adapter.
- an anchor oligo dT primer in which an anchor sequence is linked to the 5 ′ end of an oligo dT primer is used, and the oligo of the anchor oligo dT primer is used.
- An inhibition primer may be designed using the base sequence of the anchor sequence portion 5 ′ to the (dT) portion as a primer.
- the extension reaction after the inhibition primer can be inhibited by applying a modification such as a phosphate group, amino group, dideoxyl NTP and the like that can inhibit the extension reaction in PCR on the 3 ′ side of the inhibition primer.
- a modification such as a phosphate group, amino group, dideoxyl NTP and the like that can inhibit the extension reaction in PCR on the 3 ′ side of the inhibition primer.
- FIG. 2 shows the principle of elongation inhibition by the inhibitory primer of the present invention and the positional relationship between the target gene (double strand shown in the center black), adapter and primer.
- an adapter that does not contain uracil is used as the adapter.
- FIG. 2A shows the case where no inhibition primer is used.
- the adapter binds to both ends of the target gene.
- the forward primer consisting of the sequence of the adapter sense strand (long chain) is annealed to the adapter at both ends of the target gene, and even when only the forward primer is added as a primer, the extension by the forward primer is in the direction of the arrow of 2 (F). Will happen.
- FIG. 2 shows the principle of elongation inhibition by the inhibitory primer of the present invention and the positional relationship between the target gene (double strand shown in the center black), adapter and primer.
- FIG. 2A shows the case where no inhibition primer is used.
- the adapter binds to both ends of the target gene.
- the forward primer is theoretically an adapter. No annealing occurs and no elongation occurs.
- the antisense strand of the adapter that remains free without binding to the target gene anneals to the sense strand of the adapter and acts as a reverse primer, from which the extension extends in the direction of 2 (R) It may happen.
- the forward primer anneals to the complementary strand, and the extension occurs in the method indicated by the arrow 2 (F).
- FIG. 2B shows the case where an inhibition primer is used, where 1 is the extension by the target gene-specific reverse primer and 2 (F) is the forward primer consisting of the sequence of the adapter sense strand (the adapter long strand of FIG. 2).
- Extension (2) indicates extension when the adapter acts as a reverse primer.
- 3 represents the inhibitory primer of the present invention, and extension in the 2 (R) direction is inhibited by the inhibitory primer portion.
- the inhibitory primer shown in FIG. 2B consists of the sequence of the sense strand of the adapter and is modified on the 3 ′ side.
- Inhibitory primers include part of the adapter or anchor sequence portion of the anchor oligo dT primer.
- the adapter is preferably an adapter containing uracil in the antisense strand described in 1 above, but even when an adapter containing no uracil is used, unbiased growth is possible by the action of the inhibitory primer.
- the inhibitory primer of the present invention enables unbiased PCR amplification when used alone, but may be used in combination with the adapter of the present invention described in 1 above.
- gene amplification extends in one direction as described in 1 above.
- the extension reaction proceeds in one direction by linking a modification that inhibits the PCR extension reaction such as an amino group to the 3 ′ end of the antisense strand.
- the extension reaction is intended to proceed in one direction, it is best to use an adapter containing 1 uracil, but it is an adapter that does not contain uracil and has an amino group or the like at the 3 ′ end of the antisense strand.
- a unidirectional extension reaction can also be achieved by the combined use of an adapter linked with a modification that inhibits the PCR extension reaction and the inhibitory primer of the present invention.
- the inhibition primer of the present invention includes a primer having a phosphate group bound to the 3 ′ end of a nucleotide comprising the nucleotide sequence represented by SEQ ID NO: 18 (TO979), and the NotI restriction represented by SEQ ID NO: 1
- primers consisting of a base sequence 5 'to the oligo dT portion of an oligo dT primer (TO903 oligo (dT) NotI) linked with an anchor sequence having an enzyme site.
- Example 1 Gene-specific unbiased amplification method using an adapter CDNA synthesis from RNA Up to 10 ⁇ g of total RNA was prepared from mouse spleen cells, and the first strand was synthesized using an oligo dT primer (TO903) having the following sequence. Oligo dT primer TO903 oligo (dT) Not1: 5'-ataagaatgcggccgctaaactatttttttttttttttttttttttttttttttt-3 '(SEQ ID NO: 1)
- RNA ⁇ 10 ⁇ g 10 mM dNTP (Invitrogen TM), 50 ⁇ M oligo dT primer (TO903), 5x first strand buffer (Invitrogen TM), 0.1 M DTT (Invitrogen TM), RNase out (Invitrogen TM) , 200 units / ⁇ l SuperScript III (Invitrogen TM)
- Second strand synthesis was performed.
- the following reagents were mixed with the above synthesized product, and a synthesis reaction was performed at 16 ° C. for 120 minutes.
- T4 DNA polymerase (TOYOBO) was added (7 units / ⁇ l) and reacted at 16 ° C. for 5 minutes to smooth the ends of the cDNA.
- Adapter binding reaction The following oligo DNAs, TO1011 and TO995, were synthesized as the sense strand and the antisense strand of the adapter.
- the framed part of the sense strand TO1011 of SEQ ID NO: 2 is the sequence of the forward primer that anneals to the adapter.
- the sequence of the antisense strand TO995 of SEQ ID NO: 2 is an underlined complementary strand expressed in italics of TO01011 of SEQ ID NO: 2, and anneals to this portion to form a double-stranded adapter.
- P in TO995 indicates that a phosphate group is bonded
- NH 2 indicates that an amino group is bonded.
- the above TO1011 and TO995 (containing deoxyuracil) oligo DNAs were annealed to prepare adapters.
- the cDNA synthesized in 1 (1-2 ⁇ g) and the prepared adapter (20 ng / ml) were reacted with DNA ligase at 16 ° C. for 60 minutes for binding.
- reaction solution was mixed as follows. 10x Buffer for KOD Plus Ver.2, 2 mM dNTPs, 25 mM MgSO 4, 5 ⁇ M F-primer (TO1022), 5 ⁇ M R-primer (TO945), DMSO, KOD Plus (1 units / ⁇ l), UNG (2 unit / ⁇ l)
- the sequences of forward primer (F-primer) TO1022 and reverse primer (R-primer) TO945 (MCA195) were as follows.
- the reverse primer (R-primer) TO945 anneals to a sequence specific to the C region of the mouse T cell receptor (TCR) ⁇ chain.
- PCR forward primer TO 1022 5'-gcatgtacccatacgatgatcacc-3 '(SEQ ID NO: 4)
- the sequence number is the sequence of the framed portion of the TO1011.
- Reverse primer for PCR design a specific primer you want to amplify.
- alpha chain beta chain of mouse TCR For mouse TCR ⁇ chain (mouse TCR c region) TO945 (MCA195): 5'- agg tga agc ttg tct ggt tgc tc -3 '(SEQ ID NO: 5)
- TO945 for mouse TCR ⁇ chain was used as a forward primer, but TO1031 for mouse TCR ⁇ chain was also designed.
- the uracil-DNA glycosylase UNG
- the uracil-DNA glycosylase UNG
- the abasic site from which uracil was removed was decomposed by reacting at 95 ° C. for 2 min, and the TO995 portion, which is the antisense site of the adapter, was decomposed.
- a normal PCR reaction was performed. The test was conducted at 95 ° C, 30 ° sec, 60 ° C, 30 ° sec, 68 ° C, 60 ° sec for 30 cycles. At this time, the specific amplification sensitivity with PCR primers was increased by adding DMSO (Dimethyl sulfoxide). Gel extraction was performed after completion
- DMSO Dimethyl sulfoxide
- the DNA used is mouse TCR ⁇ chain cDNA (VA18-1) cDNA.
- the adapter was designed so that the base length of the sense strand and the antisense strand was the same, the base length was 25 bp or 45 bp, and uracil appeared every 5 bases, every 10 bases, or every 20 bases.
- the sequence of the sense strand and the antisense strand of the adapter used was as follows.
- the forward primer and reverse primer sequences used for the above adapters were as follows.
- Reverse primer (TO945 (MCA195) Sequence complementary to C region of mouse TCR 5'- aggtgaagcttgtctggttgctc -3 '(SEQ ID NO: 5)
- Figure 4 shows the results.
- Figure 4 shows the case of using a 25 bp adapter with a frequency of uracil every 5 bp, every 10 bp or every 20 bp, and each case with a 45 bp adapter with a frequency of uracil every 5 bp, every 10 bp or every 20 bp. Shows the results with and without UNG processing.
- the base length of the adapter should be about 25 bp, and it is better to insert uracil at a frequency of 1 or more in 5 bp.
- NOD mouse diabetes model mouse
- Reverse primer (TO945 (MCA195) Sequence complementary to C region of mouse TCR 5'- aggtgaagcttgtctggttgctc -3 '(SEQ ID NO: 22)
- the adapter used in this example is not an adapter containing uracil in the antisense strand used in Example 1, but an amino group is linked to the 3 ′ side of the antisense strand.
- the modification with the amino group can inhibit the extension only by the forward primer, and enables extension in one direction.
- the cDNA provided with the adapter was prepared so that 25 ng was contained per sample.
- reaction solution was mixed as follows. 10x Buffer for KOD Plus Ver.2, 2 mM dNTPs, 25 mM MgSO 4, 5 ⁇ M F-primer (TO993), 5 ⁇ M R-primer (TO945), DMSO, KOD Plus (1 units / ⁇ l), 5 ⁇ M Inhibit primer (TO979 ).
- PCR reaction was performed. The test was conducted at 95 ° C, 30 ° sec, 60 ° C, 30 ° sec, 72 ° C, 60 ° sec for 30 cycles. Gel extraction was performed after completion
- Lanes 1 and 3 in FIG. 6A are the cases where the forward primer (TO993) and the reverse primer (MCA195) are added, and gene amplification is observed.
- extension by the reverse primer occurs, and then extension by the forward primer occurs.
- Lanes 2 and 4 show the case where only the forward primer (TO993) was added.
- extension by the reverse primer MCA195
- the antisense strand of the free remaining adapter acts as a reverse primer, and as a result, extension by only the forward primer has occurred.
- FIG. 6B shows the case where the inhibition primer (TO979) is added in addition to the forward primer (TO993) and the reverse primer (MCA195).
- MCA195 reverse primer
- Lane 4 in FIG. 6B shows the case where only the forward primer (TO993) and the inhibition primer (TO979) are added.
- the inhibition primer is annealed to the 3 ′ side, so the extension is inhibited. As a result, extension by only the forward primer does not occur.
- Example 5 Comparison method of analysis result of TCR chain by flow cytometry and analysis result of next generation sequencer TCR chain abundance analysis by flow cytometry
- Lymphocytes were collected from lymph nodes of BALB / c mice. The presence ratio of TCR chains was examined using fluorescently labeled antibodies. To 1 ⁇ 10 6 lymphocytes, 0.25 ⁇ g of a commercially available fluorescently labeled antibody was added and stained at 4 ° C. for 30 minutes, and then the cells were washed twice with PBS. Moreover, in order to label dead cells, it dye
- the fluorescent labeled antibodies used are as follows. Anti-CD4 antibody (clone name: GK1.5) Anti-CD8 antibody (clone name 53-6.7) Anti-V ⁇ 2 antibody (clone name B20.6) Anti-V ⁇ 11 antibody (clone name B20.6) Anti-Vb8.1.2 antibody (clone name KJ16-133.18)
- CD4 and CD8 positive cells were first defined as T cells.
- the number of cells expressing the target TCR (V ⁇ 2, V ⁇ 11, V ⁇ 8.1 / 8.2) in T cells was examined.
- the number of target TCR expressing cells / the number of T cells ⁇ 100 (%) was displayed.
- the next-generation sequencer was Roche454GS Junior, and samples were analyzed according to the manufacturer's protocol.
- the result of this example shows the accuracy of the method using the adapter of the present invention.
- Example 6 Comparative Experiment Method of Equally Amplifying Five Types of Mouse TCRs Different in Size
- the following mouse TCR cDNA fragments with different sizes were prepared (TCR ⁇ chain gene containing C region, about 50 bp shorter). 1) 633bp 25ng / ⁇ l 2) 569bp 25ng / ⁇ l 3) 517bp 25ng / ⁇ l 4) 459bp 25ng / ⁇ l 5) 409bp 25ng / ⁇ l
- Each 20 ⁇ l was mixed to make a fragment mix 100 ⁇ l (final concentration of each cDNA 5 ng / ⁇ l).
- a human tissue cDNA library was prepared, and the old adapter and the new adapter were assigned to each.
- Sample 1 and sample 2 were each amplified by the PCR method.
- the new adapter was subjected to PCR after the treatment according to the present invention (after UNG treatment).
- the conditions for PCR are as follows for both the old adapter sample (sample 1) and the new adapter sample (sample 2). 98 °C 10 sec 64 °C 30 sec 68 °C 60 sec x 25 cycle
- Primer concentration, PCR buffer, and enzyme (KOD polymerase) are the same as the PCR conditions of the present invention.
- Primer forward primer for the cDNA sample (sample 1) with the PCR primer old adapter: (TO904: 5'-gacgatgacgaccgaattcc-3 '(SEQ ID NO: 23))
- Reverse primer (TO945: 5'-aggtgaagcttgtctggttgctc-3 '(SEQ ID NO: 25)) Sequence complementary to the C region of mouse TCR
- Primer forward primer for cDNA sample with new adapter (sample 2): (TO1022: 5'-gcatgtacccatacgatgatcacc-3 '(SEQ ID NO: 26))
- Reverse primer (TO945: 5'-aggtgaagcttgtctggttgctc -3 '(SEQ ID NO: 25)) Sequence complementary to the C region of mouse TCR
- Samples 1 and 2 were each amplified by the PCR method, analyzed with a bioanalyzer Agilent 2100 (manufactured by Agilent Technologies), and illustrated.
- FIG. 8 A shows the result when five different sizes of mouse TCR were mixed equally, B shows the result of the conventional amplification method with the old adapter, and C shows the amplification method of the present invention with the new adapter.
- B shows the result of the conventional amplification method, a band cannot be confirmed, and a non-specific one is amplified. This result shows that bias gene amplification occurred in conventional AL-PCR.
- C in the amplification method of the present invention using the double-stranded adapter DNA of the present invention, 5 bands were confirmed, and the length of about 50 bp gene length was obtained by adding the adapter in which the target gene was properly amplified. Extended. That is, it was confirmed that non-biased gene amplification was occurring.
- FIG. 9A shows the abundance ratio of each TCR in a mouse TCR equivalent mixture of five different sizes before PCR
- FIG. 9B shows the abundance ratio of each TCR after PCR using the adapter of the present invention.
- the abundance ratio of TCR in the conventional AL-PCR amplification using the old adapter, it was impossible to measure the abundance ratio of TCR.
- the abundance ratio hardly changed even when the sizes were different.
- the conventional AL-PCR resulted in a biased amplification result due to nonspecific gene amplification.
- the target gene amplification was obtained, and even if the size was different, the amplification was less biased.
- the abundance ratio was almost the same as the original one, and amplification was performed with little bias.
- the results of this example show the accuracy of the method using the double-stranded adapter DNA of the present invention.
- TCR may be classified into other repertoires due to a difference of several bases. If the gene amplification is accurate, the exact TCR abundance can be analyzed. For accurate TCR abundance analysis, it is desirable that the base sequence match rate be 90% or more. In this example, a comparison was made of the accuracy of gene amplification during TCR repertoire analysis.
- Sample 1 and sample 2 were each amplified by the PCR method.
- the new adapter was subjected to PCR after the treatment according to the present invention (after UNG treatment).
- the conditions for PCR are as follows for both the old adapter sample (sample 1) and the new adapter sample (sample 2). 98 °C 10 sec 64 °C 30 sec 68 °C 60 sec x 30 cycle
- Adapter array Old adapter Sense (TO904: 5'-gacgatgacgaccgaattcc-3 '(SEQ ID NO: 23))
- Antisense (TO932: 5'-ggaattcggtcgtc -3 '(SEQ ID NO: 24))
- Primer forward primer for the cDNA sample (sample 1) with the PCR primer old adapter: (TO904: 5'-gacgatgacgaccgaattcc-3 '(SEQ ID NO: 23))
- Reverse primer (TO945: 5'-aggtgaagcttgtctggttgctc-3 '(SEQ ID NO: 25)) Sequence complementary to the C region of mouse TCR
- Primer forward primer for cDNA sample with new adapter (sample 2): (TO1022: 5'-gcatgtacccatacgatgatcacc-3 '(SEQ ID NO: 26)) Reverse primer: (TO945: 5'-aggtgaagcttgtctggttgctc-3 '(SEQ ID NO: 25)) Sequence complementary to the C region of mouse TCR
- the gene of the TCR chain was amplified by PCR and used as an analysis sample.
- the next-generation sequencer was Roche454GS Junior, and samples were analyzed according to the manufacturer's protocol.
- the sequence of the V region was compared with the gene sequence presented in the IMGT (the International Immuno GeneTics information system for immunoglobulin insulin or Web site).
- the sequence of the target TCR-V region shown in IMGT was taken as 100%, and how much the TCR-V sequence of the sample matched was calculated. Analyzed sample TCR V region sequence / Full length sequence of target V region by IMGT ⁇ 100 (%)
- the distribution of the match rate was calculated by the following calculation. Number of TCRs with a match rate of XX% / Total number of TCRs x 100
- the above match rates are classified by range from A to F and shown in the figure.
- the match rate belongs to the following range. A: 0-59%, B: 60-69%, C: 70-79%, D 80-89%, E: 90-99%, F: 100%
- the adapter ligation PCR (AL-PCR) of the conventional method showed a low TCR gene match rate (black).
- the TCR gene matching rate is high (90% or more matched genes are 80% or more), and specific gene amplification is performed accurately. (White). If the TCR gene coincidence rate is high, there are few errors during analysis, and the TCR ratio in the living body can be reflected.
- the results of this example show the accuracy of the method using the double-stranded adapter DNA of the present invention.
- the gene-specific non-bias amplification method of the present invention can comprehensively amplify and analyze genes having various repertoires such as T cell receptor (TCR) and B cell receptor (BCR), and is disease specific. It can also be used in clinical practice, such as identifying the correct TCR. All publications, patents and patent applications cited in this specification shall be incorporated into this specification as they are.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
[1] 以下の特徴を有する非バイアス遺伝子増幅に用いる2本鎖アダプターDNA:
(a) センス鎖とアンチセンス鎖がアニーリングしており、センス鎖とアンチセンス鎖の塩基長は同じであるか、又はセンス鎖が長い;
(b) センス鎖の塩基長は15~40bpである;
(c) アンチセンス鎖に複数のウラシルを含み、ウラシルDNAグリコシラーゼ(UNG)でアダプターを処理することにより、ウラシルが除去され、その後加熱処理することによりアンチセンス鎖が分解される;
(d) アダプターDNAの少なくとも1端は平滑末端の形態を有する;
(e) 一方の末端で増幅しようとする標的遺伝子に結合する;及び
(f) センス鎖の一部又は全部が遺伝子増幅に用いるフォワードプライマーの配列である。
[2] アンチセンス鎖に含まれるウラシルの数がアンチセンス鎖の塩基数の10~25%であり、5~10塩基ごとにウラシルが存在する、[1]の2本鎖アダプターDNA。
[3] アンチセンス鎖の5'末端にリン酸基が結合しており、3'末端にアミノ基が結合している、[1]又は[2]の2本鎖アダプターDNA。
[4] [1]~[3]のいずれかのアダプターDNAと該アダプターDNAのセンス鎖の一部又は全部の配列からなるプライマーを含む、非バイアス遺伝子増幅キット。
[5] 2本鎖アダプターDNA及び2本鎖アダプターDNAのセンス鎖の一部配列からなるフォワードプライマーを用いるアダプターライゲーションPCR増幅法において、フォワードプライマーのみによる遺伝子増幅を阻害することにより、非バイアス遺伝子増幅を行うために用いる阻害プライマーであって、
(a) 該阻害プライマーの配列は、
(i) 増幅しようとする標的遺伝子のmRNAから1本鎖cDNAを合成するときに用いる、オリゴdTプライマーの5'末端にアンカー配列を連結させたアンカーオリゴdTプライマーのアンカー配列部分の全部又は一部配列からなるか、若しくは
(ii) アダプターライゲーションPCR増幅法に用いる2本鎖アダプターのセンス鎖の一部配列であって、前記のフォワードプライマーの配列より3'側に存在する配列からなり、
(b) 3'側がリン酸基、アミノ基若しくはジデオキシルNTPで修飾されている、阻害プライマー。
[6] [1]~[3]のいずれかのアダプターDNAと該アダプターDNAのセンス鎖の一部又は全部の配列からなるプライマーと[5]の阻害プライマーを含む、非バイアス遺伝子増幅キット。
[7] 以下の工程を含む、標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法:
(i) 2本鎖cDNAの両端に[1]~[4]のいずれかの2本鎖アダプターDNAをライゲーションする工程;
(ii) 2本鎖アダプターDNAをライゲーションした遺伝子をウラシルDNAグリコシラーゼ(UNG)で処理し、さらに加熱処理することによりアダプターDNAのアンチセンス鎖を分解する工程;
(iii) 2本鎖アダプターDNAのセンス鎖の一部又は全部の配列からなるフォワードプライマー及び標的遺伝子に特異的にアニーリングするリバースプライマーを用いてPCR増幅を行う工程。
[8] フォワードプライマーのみによる伸長反応は起こらず、リバースプライマーによる伸長反応が起こり、アダプターのセンス鎖の相補鎖が形成された後に、該相補鎖にフォワードプライマーがアニーリングし伸長反応が起こり、リバースプライマーによる伸長及びフォワードプライマーによる伸長がこの順序で一方向に起こる、[7]の標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法。
[9] さらに、[5]の阻害プライマーを用いることによりフォワードプライマーのみによる伸長反応を阻害する、[7]又は[8]の標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法。
[10] T細胞又はB細胞から抽出したトータルRNAからcDNAを合成し、リバースプライマーとして、T細胞受容体(TCR)又はB細胞受容体(BCR)のC領域の配列に特異的にアニーリングするプライマーを用いてTCR遺伝子又はBCR遺伝子のレパートリーを、[7]又は[8]の方法により網羅的に増幅し、シーケンサーにより配列決定を行うことを含む、TCR又はBCRのレパートリーの分析方法。
本発明のアダプターは、センス鎖とアンチセンス鎖からなり、これらがアニーリングしている2本鎖DNAである。本発明において、アダプターをアダプターDNAともいう。アダプターの一方の鎖は一定の頻度でウラシル(dUTP:デオキシウリジン三リン酸)を含んでいる。以下、アダプターのアンチセンス鎖にウラシルが含まれる場合について説明する。以下の説明において、センス鎖とアンチセンス鎖を置き換えることができる。アンチセンス鎖に相補的なセンス鎖部分における、アンチセンス鎖のウラシルに対応する塩基はアデニンとなる。センス鎖とアンチセンス鎖の塩基長は同じでもよく、ウラシルを含むアンチセンス鎖が短くてもよい。アダプターは少なくとも一端が平滑末端の形態を有している。アンチセンス鎖がセンス鎖より短い場合、アダプターの一端は平滑末端の形態を有しており、もう一端は突出末端の形態を有しており、平滑末端側で増幅しようとする標的遺伝子にライゲーションして用いる。センス鎖とアンチセンス鎖の塩基長が同じ場合、アダプターの両端は平滑末端の形態を有している。
(1)配列番号2に表される塩基配列からなるセンス鎖と配列番号3に表される塩基配列からなるアンチセンス鎖であって、5'末端をリン酸化したアンチセンス鎖をアニーリングさせたアダプター。アンチセンス鎖の3'末端にアミノ基を結合させてもよい。このアダプターは、リン酸基が結合した末端が平滑末端の形態を有し、他端は突出末端の形態を有する。このアダプターを用いる場合、フォワードプライマーとして、配列番号4に表される塩基配列からなるプライマーを用いる。
(2)配列番号8に表される塩基配列からなるセンス鎖と配列番号9に表される塩基配列からなるアンチセンス鎖であって、5'末端をリン酸化したアンチセンス鎖をアニーリングさせたアダプター。アンチセンス鎖の3'末端にアミノ基を結合させてもよい。このアダプターは、両端が平滑末端の形態を有する。このアダプターを用いる場合、フォワードプライマーとして、配列番号17に表される塩基配列からなるプライマーを用いる。
(3)配列番号8に表される塩基配列からなるセンス鎖と配列番号10に表される塩基配列からなるアンチセンス鎖であって、5'末端をリン酸化したアンチセンス鎖をアニーリングさせたアダプター。アンチセンス鎖の3'末端にアミノ基を結合させてもよい。このアダプターは、両端が平滑末端の形態を有する。このアダプターを用いる場合、フォワードプライマーとして、配列番号17に表される塩基配列からなるプライマーを用いる。
(4)配列番号8に表される塩基配列からなるセンス鎖と配列番号11に表される塩基配列からなるアンチセンス鎖であって、5'末端をリン酸化したアンチセンス鎖をアニーリングさせたアダプター。アンチセンス鎖の3'末端にアミノ基を結合させてもよい。このアダプターは、両端が平滑末端の形態を有する。このアダプターを用いる場合、フォワードプライマーとして、配列番号17に表される塩基配列からなるプライマーを用いる。
本発明の遺伝子増幅方法は、フォワードプライマーとして、上記のアダプターのセンス鎖の全部又は一部の配列からなり、アダプターのセンス鎖に内在する配列を有するアダプター用フォワードプライマーを用い、リバースプライマーとして増幅させようとする標的遺伝子の3'末端近傍にアニーリングするプライマーを用いる。
本発明の遺伝子増幅法により、T細胞受容体(TCR)やB細胞受容体(BCR)等の抗原受容体のレパートリーを偏りなく分析することができる。
本発明はアダプターライゲーションPCR増幅法において、非バイアス遺伝子増幅に用いる阻害プライマーも包含する。
1. RNAからのcDNA合成
10μgまでのtotal RNAをマウス脾臓細胞から準備し、以下の配列を有するオリゴdTプライマー(TO903)を用いて第1鎖(first strand)合成を行った。
オリゴdTプライマー
TO903 oligo (dT) Not1:5'- ataagaatgcggccgctaaactatttttttttttttttttt -3' (配列番号1)
Total RNA ~10μg, 10mM dNTP (Invitrogen(商標)), 50μM オリゴdTプライマー(TO903), 5x first strand buffer (Invitrogen(商標)), 0.1 M DTT (Invitrogen(商標)), RNase out (Invitrogen(商標), 200 units/μl SuperScript III (Invitrogen(商標))
5x 2nd strand buffer (Invitrogen(商標)), 10mM dNTPs (Invitrogen(商標)), E.coli DNA ligase (10 units/μl) (Invitrogen(商標)), E.coli DNA polymerase1 (10 units/μl) (Invitrogen(商標)), RNase H (2 units/μl) (Invitrogen(商標))
アダプターのセンス鎖とアンチセンス鎖として、以下のオリゴDNA、TO1011及びTO995を合成した。
アダプター付与したcDNAは1サンプルあたり25ng含まれるように調製した。
10x Buffer for KOD Plus Ver.2, 2 mM dNTPs, 25 mM MgSO4, 5μM F-primer (TO1022), 5μM R-primer (TO945), DMSO, KOD Plus (1 units/μl), UNG (2 unit/μl)
TO 1022: 5'- gcatgtacccatacgatgatcacc -3'(配列番号4)
配列番号は、上記TO1011の枠囲み部分の配列である。
マウスTCRα鎖用 (マウスTCR c領域)
TO945(MCA195): 5'- agg tga agc ttg tct ggt tgc tc -3'(配列番号5)
TO 1031: 5'- cactgtggacctccttgccattc -3'(配列番号6)
1の増幅法において用いるアダプター配列の検討を行った。
ウラシルを挿入する前の元となるセンス鎖(GC含量:50%)
5'-gcatgtacccatacgatgatcacg-3' (配列番号7)
アダプターのGC含量:48%
センス鎖の枠囲み部分はフォワードプライマーの配列を示す。
Pはリン酸基が結合していることを表し、NH2はアミノ基が結合していることを表す。
ウラシルを挿入する前の元となるセンス鎖(GC含量:51.1%)
5'-gcatgtacccatacgatgatcaccggacagaccatgtactacgag-3'(配列番号12)
アダプターのGC含量:51.1%
センス鎖の枠囲み部分はフォワードプライマーの配列を示す。
Pはリン酸基が結合していることを表し、NH2はアミノ基が結合していることを表す。
5'-gcatctgactgtacgtgatc-3' (配列番号17)
5'- aggtgaagcttgtctggttgctc -3' (配列番号5)
前項で示す方法を用いて、TCR網羅的解析を次世代シークエンサー(Roche 454 GS Junior)にて行った。結果を図5に示す。
TO993: 5'- cac atg gat gac gat ca cag -3' (配列番号21)
5'- aggtgaagcttgtctggttgctc -3' (配列番号22)
10x Buffer for KOD Plus Ver.2, 2 mM dNTPs, 25 mM MgSO4, 5μM F-primer (TO993), 5μM R-primer (TO945) , DMSO, KOD Plus (1 units/μl), 5μM Inhibit primer (TO979).
1.フローサイトメトリーによるTCR鎖の存在比率解析
BALB/cマウスのリンパ節からリンパ球を採取した。蛍光標識抗体を用いて、TCR鎖の存在比率を検討した。1x106個のリンパ球に対し、市販の蛍光標識抗体を0.25μgを加え、4℃、30分間染色し、その後、PBSにて細胞を2回洗った。また、死細胞を標識するため、PI(Propidium Iodide)を用いて染色し、解析サンプルとした。このサンプルを用いて、フローサイトメトリーにて解析した。フローサイトメトリー解析はFACSCanto II (Becton Dickinson社製)にて行った。
用いた蛍光標識抗体は、以下である。
抗CD4抗体(クローン名GK1.5)
抗CD8抗体(クローン名53-6.7)
抗Vβ2抗体(クローン名B20.6)
抗Vβ11抗体(クローン名B20.6)
抗Vb8.1.2抗体(クローン名KJ16-133.18)
BALB/cマウスのリンパ節から、total RNAを抽出、通法によりcDNA libraryを作成した。本発明による方法を用いて、今回発明の新アダプターを付与し、非バイアス遺伝子増幅法によるPCRを行ってTCR鎖の遺伝子増幅を行い、これを解析サンプルとした。次世代シークエンサーは、Roche454GS Juniorを用い、メーカーのプロトコールに従って、サンプルを解析した。
実験方法
1. 以下のサイズの異なるマウスTCR cDNA fragmentを用意した(C領域を含むTCRα鎖遺伝子、約50bpごと短い)。
1) 633bp 25ng/μl
2) 569bp 25ng/μl
3) 517bp 25ng/μl
4) 459bp 25ng/μl
5) 409bp 25ng/μl
それぞれ20μlずつ混合、fragment mix 100μlとした(それぞれのcDNAの終濃度5ng/μl).
98℃ 10 sec
64℃ 30 sec
68℃ 60 sec
x 25 cycle
旧アダプター
Sense:(TO904: 5’-gacgatgacgaccgaattcc-3’(配列番号23))
Antisense:(TO932: 5’-ggaattcggtcgtc -3’(配列番号24))
旧アダプター付与したcDNAサンプル(サンプル1)に対するプライマー
フォワードプライマー:(TO904: 5’-gacgatgacgaccgaattcc-3’(配列番号23))
リバースプライマー:(TO945: 5’-aggtgaagcttgtctggttgctc -3’(配列番号25))マウスTCRのC領域に相補的な配列
フォワードプライマー:(TO1022: 5’-gcatgtacccatacgatgatcacc -3’(配列番号26))
TCRは数塩基の違いで、他のレパートリーに分類される場合がある。遺伝子増幅が正確であれば、正確なTCRの存在比を解析できる。正確なTCRの存在比解析には、塩基配列一致率が90%以上であることが望ましい。本実施例では、TCRレパートリー解析時の遺伝子増幅の正確性の比較を検討した。
1. BALB/cマウスのリンパ節から、total RNAを抽出、通法によりcDNA libraryを作成した。従来のアダプター(旧アダプター)、今回発明のアダプター(新アダプター)をそれぞれ付与した。旧アダプターサンプルをサンプル1、新アダプターサンプルをサンプル2とした。
98℃ 10 sec
64℃ 30 sec
68℃ 60 sec
x 30 cycle
旧アダプター
Sense:(TO904: 5’-gacgatgacgaccgaattcc-3’(配列番号23))
Antisense:(TO932: 5’-ggaattcggtcgtc -3’(配列番号24))
PCRプライマー
旧アダプター付与したcDNAサンプル(サンプル1)に対するプライマー
フォワードプライマー:(TO904: 5’-gacgatgacgaccgaattcc-3’(配列番号23))
リバースプライマー:(TO945: 5’-aggtgaagcttgtctggttgctc -3’(配列番号25))マウスTCRのC領域に相補的な配列
フォワードプライマー:(TO1022: 5’-gcatgtacccatacgatgatcacc -3’(配列番号26))
リバースプライマー:(TO945: 5’-aggtgaagcttgtctggttgctc -3’(配列番号25))マウスTCRのC領域に相補的な配列
解析したサンプルのTCRのV領域の配列 / IMGTにて目的のV領域の全長配列 ×100(%)
一致率が○○%であったTCR数 / 全TCR数 ×100(%)
上記の一致率をAからFまで範囲ごとに分類し、図示した。
一致率が以下の範囲に属する。
A: 0-59%, B: 60-69%, C: 70-79%, D 80-89%, E: 90-99%, F: 100%
配列番号2、3、7~16、19、20 合成
Claims (10)
- 以下の特徴を有する非バイアス遺伝子増幅に用いる2本鎖アダプターDNA:
(a) センス鎖とアンチセンス鎖がアニーリングしており、センス鎖とアンチセンス鎖の塩基長は同じであるか、又はセンス鎖が長い;
(b) センス鎖の塩基長は15~40bpである;
(c) アンチセンス鎖に複数のウラシルを含み、ウラシルDNAグリコシラーゼ(UNG)でアダプターを処理することにより、ウラシルが除去され、その後加熱処理することによりアンチセンス鎖が分解される;
(d) アダプターDNAの少なくとも1端は平滑末端の形態を有する;
(e) 一方の末端で増幅しようとする標的遺伝子に結合する;及び
(f) センス鎖の一部又は全部が遺伝子増幅に用いるフォワードプライマーの配列である。 - アンチセンス鎖に含まれるウラシルの数がアンチセンス鎖の塩基数の10~25%であり、5~10塩基ごとにウラシルが存在する、請求項1記載の2本鎖アダプターDNA。
- アンチセンス鎖の5'末端にリン酸基が結合しており、3'末端にアミノ基が結合している、請求項1又は2に記載の2本鎖アダプターDNA。
- 請求項1~3のいずれか1項に記載のアダプターDNAと該アダプターDNAのセンス鎖の一部又は全部の配列からなるプライマーを含む、非バイアス遺伝子増幅キット。
- 2本鎖アダプターDNA及び2本鎖アダプターDNAのセンス鎖の一部配列からなるフォワードプライマーを用いるアダプターライゲーションPCR増幅法において、フォワードプライマーのみによる遺伝子増幅を阻害することにより、非バイアス遺伝子増幅を行うために用いる阻害プライマーであって、
(a) 該阻害プライマーの配列は、
(i) 増幅しようとする標的遺伝子のmRNAから1本鎖cDNAを合成するときに用いる、オリゴdTプライマーの5'末端にアンカー配列を連結させたアンカーオリゴdTプライマーのアンカー配列部分の全部又は一部配列からなるか、若しくは
(ii) アダプターライゲーションPCR増幅法に用いる2本鎖アダプターのセンス鎖の一部配列であって、前記のフォワードプライマーの配列より3'側に存在する配列からなり、
(b) 3'側がリン酸基、アミノ基若しくはジデオキシルNTPで修飾されている、阻害プライマー。 - 請求項1~3のいずれか1項に記載のアダプターDNAと該アダプターDNAのセンス鎖の一部又は全部の配列からなるプライマーと請求項5記載の阻害プライマーを含む、非バイアス遺伝子増幅キット。
- 以下の工程を含む、標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法:
(i) 2本鎖cDNAの両端に請求項1~4のいずれか1項に記載の2本鎖アダプターDNAをライゲーションする工程;
(ii) 2本鎖アダプターDNAをライゲーションした遺伝子をウラシルDNAグリコシラーゼ(UNG)で処理し、さらに加熱処理することによりアダプターDNAのアンチセンス鎖を分解する工程;
(iii) 2本鎖アダプターDNAのセンス鎖の一部又は全部の配列からなるフォワードプライマー及び標的遺伝子に特異的にアニーリングするリバースプライマーを用いてPCR増幅を行う工程。 - フォワードプライマーのみによる伸長反応は起こらず、リバースプライマーによる伸長反応が起こり、アダプターのセンス鎖の相補鎖が形成された後に、該相補鎖にフォワードプライマーがアニーリングし伸長反応が起こり、リバースプライマーによる伸長及びフォワードプライマーによる伸長がこの順序で一方向に起こる、請求項7記載の標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法。
- さらに、請求項5に記載の阻害プライマーを用いることによりフォワードプライマーのみによる伸長反応を阻害する、請求項7又は8に記載の標的遺伝子を一方向にバイアスをかけずにPCR法により増幅させる方法。
- T細胞又はB細胞から抽出したトータルRNAからcDNAを合成し、リバースプライマーとして、T細胞受容体(TCR)又はB細胞受容体(BCR)のC領域の配列に特異的にアニーリングするプライマーを用いてTCR遺伝子又はBCR遺伝子のレパートリーを、請求項7又は8に記載の方法により網羅的に増幅し、シーケンサーにより配列決定を行うことを含む、TCR又はBCRのレパートリーの分析方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017502372A JP6793956B2 (ja) | 2015-02-23 | 2016-02-23 | 遺伝子特異的非バイアス増幅法 |
EP16755460.9A EP3263716B1 (en) | 2015-02-23 | 2016-02-23 | Gene-specific unbiased amplification method |
US15/552,971 US10829809B2 (en) | 2015-02-23 | 2016-02-23 | Gene-specific unbiased amplification method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015033236 | 2015-02-23 | ||
JP2015-033236 | 2015-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016136716A1 true WO2016136716A1 (ja) | 2016-09-01 |
Family
ID=56789561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/055192 WO2016136716A1 (ja) | 2015-02-23 | 2016-02-23 | 遺伝子特異的非バイアス増幅法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US10829809B2 (ja) |
EP (1) | EP3263716B1 (ja) |
JP (1) | JP6793956B2 (ja) |
WO (1) | WO2016136716A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019151392A1 (ja) | 2018-01-31 | 2019-08-08 | 国立大学法人東北大学 | 抗原特異的mhc発現調節法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015075939A1 (ja) * | 2013-11-21 | 2015-05-28 | Repertoire Genesis株式会社 | T細胞受容体およびb細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6197557B1 (en) * | 1997-03-05 | 2001-03-06 | The Regents Of The University Of Michigan | Compositions and methods for analysis of nucleic acids |
US6509157B1 (en) * | 1999-11-05 | 2003-01-21 | Roche Molecular Systems, Inc | 3 blocked nucleic acid amplification primers |
EP2702175B1 (en) * | 2011-04-25 | 2018-08-08 | Bio-Rad Laboratories, Inc. | Methods and compositions for nucleic acid analysis |
EP2769007B1 (en) * | 2011-10-19 | 2016-12-07 | Nugen Technologies, Inc. | Compositions and methods for directional nucleic acid amplification and sequencing |
WO2013191775A2 (en) | 2012-06-18 | 2013-12-27 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
WO2014160199A1 (en) * | 2013-03-14 | 2014-10-02 | Cornell University | Method for relative quantification of changes in dna methylation, using combined nuclease, ligation, and polymerase reactions |
-
2016
- 2016-02-23 WO PCT/JP2016/055192 patent/WO2016136716A1/ja active Application Filing
- 2016-02-23 US US15/552,971 patent/US10829809B2/en active Active
- 2016-02-23 EP EP16755460.9A patent/EP3263716B1/en active Active
- 2016-02-23 JP JP2017502372A patent/JP6793956B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015075939A1 (ja) * | 2013-11-21 | 2015-05-28 | Repertoire Genesis株式会社 | T細胞受容体およびb細胞受容体レパトアの解析システムならびにその治療および診断への利用 |
Non-Patent Citations (4)
Title |
---|
CHEN P. F. ET AL.: "Development of the Non- Palindromic Adaptor Polymerase Chain Reaction (NPA-PCR) for the Amplification of Alpha- and Beta-Chain T- Cell Receptor cDNAs", SCANDINAVIAN JOURNAL OF IMMUNOLOGY, vol. 35, 1992, pages 539 - 549, XP008147894, DOI: doi:10.1111/j.1365-3083.1992.tb03253.x * |
KITAURA K. ET AL.: "A new methods for quantitative analysis of the T cell receptor V rgion repertoires in healthy common marmosets by microplate hybridization assay", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 384, 2012, pages 81 - 91, XP055345569 * |
See also references of EP3263716A4 * |
TSURUTA Y. ET AL.: "Detection of human T cell receptor cDNAs(a, P, y and 5) by ligation of universal adaptor to variable region", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 161, 1993, pages 7 - 21, XP023992397, DOI: doi:10.1016/0022-1759(93)90193-B * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019151392A1 (ja) | 2018-01-31 | 2019-08-08 | 国立大学法人東北大学 | 抗原特異的mhc発現調節法 |
Also Published As
Publication number | Publication date |
---|---|
EP3263716A4 (en) | 2018-10-24 |
EP3263716B1 (en) | 2020-04-08 |
JPWO2016136716A1 (ja) | 2017-11-30 |
EP3263716A1 (en) | 2018-01-03 |
JP6793956B2 (ja) | 2020-12-02 |
US20180245130A1 (en) | 2018-08-30 |
US10829809B2 (en) | 2020-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240117420A1 (en) | Methods and compositions for multiplex pcr | |
US8278051B2 (en) | Method of amplifying a target nucleic acid by rolling circle amplification | |
EP2966180B1 (en) | Methods and compositions for multiplex pcr | |
US20150322490A1 (en) | Methods and compositions for multiplex pcr | |
US20160046979A1 (en) | Methods and compositions for multiplex pcr | |
US11390915B2 (en) | Polynucleotide adapter design for reduced bias | |
WO2013081864A1 (en) | Methods and compositions for multiplex pcr | |
WO2016136716A1 (ja) | 遺伝子特異的非バイアス増幅法 | |
EP3252168A1 (en) | Pcr primer linked to complementary nucleotide sequence or complementary nucleotide sequence including mis-matched nucleotides and method for amplifying nucleic acid using same | |
JP2022518917A (ja) | 核酸の検出方法及びプライマーの設計方法 | |
US20230193353A1 (en) | Methods and compositions for high-fidelity sequence analysis of individual long and ultralong nucleic acid molecules | |
KR101466666B1 (ko) | 열 안정성 dna 중합효소의 제조방법 및 이에 의해 제조된 dna 중합효소 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16755460 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017502372 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15552971 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2016755460 Country of ref document: EP |